Calquence approved in the US for adult patients with chronic lymphocytic leukaemia
Two Phase III Calquence trials demonstrated superior progression-free survival across multiple settings while maintaining favourable tolerability Calquence combined with obinutuzumab and as monotherapy reduced the risk of disease progression or death by 90% and 80%, respectively in ELEVATE-TNAstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).[1] The US approval was granted under the FDA’s Real-Time Oncology Review and newly
